

---

# **BIOTECH**

## **SHOWCASE™ 2024**

---

**JANUARY 8-10, 2024**

SAN FRANCISCO, CA, USA

**ADDENDUM**

---



## Conference Update

### **Company Profile Corrections**

Otovia Therapeutics  
Funds Raised: \$9M to date

Bilix, Co., Ltd.  
formally presenting in person will now be presenting virtually, see time change.

### **Presentation Time Changes**

Bilix, Co., Ltd is now presenting  
Wednesday, Jan 10, at 9:30 AM in Yosemite A  
Zenon Biotech is now presenting  
Tuesday, January 9, at 4:30 PM in Franciscan C

### **Company and Presenter Title Changes**

Acutis Diagnostic is now Acutis Biosciences and therapeutic focus is CRO, Analytical Pharma Services

### **Presenting Company Cancellations**

Aeolian Biotech Corp  
Aliris  
biotx.ai GmbH  
Brinter Inc  
Gyder Surgical Pty Ltd (DMS)  
illumicell AI (SEED)  
LexBio  
Milk Care Co., Inc.

NeuroTrauma Sciences  
Neuvivo, Inc.  
NXgenPort Inc (SEED)  
OssiFi Therapeutics LLC  
Rosebud Biosciences Inc. (SEED)  
Vector BioMed

### **Additional Presenting Companies**

Addex Therapeutics  
AutoMedicus Corporation  
Auxilius Pharma  
Bionomics Ltd  
brain4care  
capsitec  
ChainGen Biopharma Ltd  
Circio AB  
Coervative, Inc.  
Cognigenics, Inc.  
Crossject SA  
Dionysus Digital Health, Inc (SEED)  
DsciLab Co. Ltd.  
Elenae Therapeutics, Inc. (SEED)  
Embold Therapeutics, Inc. (SEED)  
Eugit Therapeutics Inc (SEED)  
Espervita Therapeutics  
GeneLancet Biosciences, Inc.  
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  
iQure Pharma  
Lactiga US, Inc.  
Lynk Pharmaceuticals Co., Ltd.

MEKanistic Therapeutics, Inc.  
Modulus Therapeutics, Inc.  
Narwhal Bio Inc. (SEED)  
NGGT Inc.  
Niconox LLC (Digital) (SEED)  
Novel Biotechnology Inc. (SEED)  
Papillon Biosciences, Inc. (SEED)  
Pattern Computer  
RND Pharmaceuticals Inc.  
Saghmos Therapeutics  
Sapphiros Ai Bio  
SHIFTBIO INC.  
Sinaptica Therapeutics Inc.  
Trilo Therapeutics  
TMAB Therapeutics, Inc. (SEED)  
UgeneX Therapeutics  
UltraSight (DMS)  
VacV Biotherapeutics Limited  
Variant Bio, Inc.  
Westlake Genetech  
YunQuan Biological Technology Co. (DMS)  
Zenon Biotech

DMS=DigiMed Showcase

**Additional Company Presentations:**

<i>Company Name</i>	<i>Presentation Date</i>	<i>Presentation Time</i>	<i>Presentation Location</i>
Coeurative, Inc.	1/8/2024	11:15 AM	Franciscan D
Trilo Therapeutics	1/8/2024	2:00 PM	Franciscan C
X` AutoMedicus Corporation	1/8/2024	2:15 PM	Franciscan B
Circio AB	1/8/2024	2:30 PM	Yosemite C
Capsitec	1/8/2024	3:15 PM	Franciscan D
Modulus Therapeutics, Inc.	1/8/2024	3:30 PM	Yosemite C
Sinaptica Therapeutics Inc.	1/8/2024	4:00 PM	Yosemite C
Variant Bio, Inc.	1/8/2024	4:15 PM	Yosemite C
Addex Therapeutics (SIX:ADXN)	1/8/2024	4:30 PM	Yosemite A
Auxilius Pharma	1/8/2024	4:30 PM	Yosemite C
brain4care	1/8/2024	4:45 PM	Yosemite C
Bionomics Ltd (NASDAQ:BNOX)	1/9/2024	4:30 PM	Yosemite A
Crossject SA (Euronext:ALCJ)	1/9/2024	4:30 PM	Yosemite C
Zenon Biotech	1/9/2024	4:30 PM	Franciscan C
Bilix, Co., Ltdx	1/10/2024	9:30 AM	Yosemite A
DsciLab Co.,Ltd.	1/10/2024	9:30 AM	Yosemite C
Lactiga US, Inc.	1/10/2024	9:45 AM	Yosemite A
MEKanistic Therapeutics, Inc.	1/10/2024	9:45 AM	Yosemite C
Narwhal Bio Inc. (SEED)	1/10/2024	9:50 AM	Franciscan C
ChainGen Biopharma Ltd	1/10/2024	10:00 AM	Yosemite A
Espervita Therapeutics	1/10/2024	10:00 AM	Yosemite C
Lynk Pharmaceuticals Co., Ltd.	1/10/2024	10:15 AM	Yosemite C
Saghmos Therapeutics	1/10/2024	10:15 AM	Yosemite A
Embold Therapeutics, Inc. (SEED)	1/10/2024	10:30 AM	Franciscan C
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541)	1/10/2024	10:30 AM	Yosemite A
Sapphiros Ai Bio	1/10/2024	10:30 AM	Yosemite C
Dionysus Digital Health, Inc (SEED)	1/10/2024	10:40 AM	Franciscan C
Westlake Genetech	1/10/2024	10:45 AM	Yosemite C
Novel Biotechnology Inc. (SEED)	1/10/2024	10:50 AM	Franciscan C
TMAB Therapeutics, Inc. (SEED)	1/10/2024	11:00 AM	Franciscan C
Cognigenics, Inc.	1/10/2024	11:00 AM	Yosemite C
GeneLancet Biosciences, Inc.	1/10/2024	11:00 AM	Yosemite A
Elenae Therapeutics, Inc. (SEED)	1/10/2024	11:10 AM	Franciscan C
iQure Pharma	1/10/2024	11:15 AM	Yosemite A
UgeneX Therapeutics	1/10/2024	11:15 AM	Yosemite C
Eugit Therapeutics Inc (SEED)	1/10/2024	11:20 AM	Franciscan C
Ultra Sight (DMS)	1/10/2024	11:30 AM	Yosemite A
Papillon Biosciences, Inc. (Digital) (SEED)	1/10/2024	11:30 AM	Franciscan C
SHIFTBIO INC.	1/10/2024	11:30 AM	Yosemite C
RND Pharmaceuticals Inc.	1/10/2024	11:45 AM	Yosemite A
VacV Biotherapeutics Limited	1/10/2024	11:45 AM	Yosemite C
Niconox LLC (Digital) (SEED)	1/10/2024	11:50 AM	Franciscan C
NGGT Inc.	1/10/2024	2:00 PM	Yosemite A
YunQuan Biological Technology Co., Ltd. (DMS)	1/10/2024	2:15 PM	Yosemite A
Pattern Computer	1/10/2024	3:15 PM	Franciscan B

DMS=DigiMed Showcase

## Conference Update

**Addex Therapeutics (SIX:ADXN)** (In-Person)**Categorical Listings:** CNS-Neurological, Drug Discovery, Neurology**Location:** Geneva, Switzerland**Year Established:** 2002 **Website:** www.addextherapeutics.com**Corporate Partners:** Janssen Pharmaceuticals is developing the company's epilepsy program and Indivior is funding the company's GABAB PAM program for substance use disorders.**Funds Raised:** More than \$350K to date - \$100K venture; \$130K IPO; \$120K in multiple follow on offerings.**Presenter:** Tim Dyer, CEO**Aliris** (In-Person)**Categorical Listings:** Drug Delivery, Gene-Cell Therapy, Infectious Disease**Location:** Newark, Delaware United States**Year Established:** 2024 **Website:** INP**Corporate Partners:** None**Funds Raised:** Raising Seed round.**Presenter:** Jinlin Jiang, PhD, Co-Founder**AutoMedicus Corporation** (In-Person)**Categorical Listings:** Cardiovascular, Drug Delivery**Location:** Pasadena, California United States**Year Established:** 2014 **Website:**

www.automedicus.com/autopress

**Corporate Partners:** None to date.**Funds Raised:** Over \$600K self funded.**Presenter:** William Harrity, MD, Co-Founder & CMO**Auxilius Pharma** (In-Person)**Categorical Listings:** Cardiovascular**Location:** Hudson, Massachusetts United States**Year Established:** 2019 **Website:** www.auxiliuspharma.com**Corporate Partners:** AUX-001 has been developed in partnership with Netherlands-based formulating lab Avivia. CTM for Phase 1a has been manufactured by Germany-based Aenova Group.

Regulatory plan was developed by Premier Consulting.

**Funds Raised:** \$2.75M to date from individual investors and EU based early stage VCs.**Presenter:** Uwe Tigör, MD, CMO**Bionomics Ltd (NASDAQ:BNOX)** (In-Person)**Categorical Listings:** CNS-Neurological**Location:** Weston, United States**Year Established:** 1996 **Website:** www.bionomics.com.au**Corporate Partners:** Bionomics has a strategic partnership with Merck & Co., Inc. with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other CNS conditions.**Funds Raised:** \$35M since Dec 2021.**Presenter:** Spyros Papapetropoulos, MD, PhD, President & CEO**brain4care** (In-Person)**Categorical Listings:** Artificial Intelligence (AI), CNS-Neurological, Diagnostics**Location:** Johns Creek, Georgia United States**Year Established:** 2017 **Website:** brain4.care/en/home-english**Corporate Partners:** There are no corporate partners at this stage. Looking for one or more to accelerate US market penetration.**Funds Raised:** \$17.3M in the last five years from friends and family offices.**Presenter:** Carlos Bremer, PhD, President, North America Division**Capsitec** (In-Person)**Categorical Listings:** Infectious Disease, Biomanufacturing, Immunology**Location:** Planegg, Germany**Year Established:** 2021 **Website:** capsitec.com**Corporate Partners:** Private**Funds Raised:** 10M plus 30 M gov**Presenter:** Hendrik Dietz, CEO**ChainGen Biopharma Ltd** (In-Person)**Categorical Listings:** CNS-Neurological, Drug Delivery, Orphan-Rare Disease**Location:** Shanghai, China**Year Established:** 2022 **Website:** INP**Corporate Partners:** Bioreainn Inc., GenScript ProBio**Funds Raised:** Seed round \$6.5M in 2022.**Presenter:** Xuefeng Zhang, Co-Founder & COO**Circio AB** (In-Person)**Categorical Listings:** Immunology, Orphan-Rare Disease**Location:** Hässelby, Sweden**Year Established:** 2022 **Website:** www.circio.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** Lubor Gaal, PhD, CFO**Coeurative, Inc.** (Virtual)**Categorical Listings:** Cardiovascular, Drug Discovery**Location:** Roanoke, Virginia United States**Year Established:** 2012 **Website:** www.coeurative.com**Corporate Partners:** INP**Funds Raised:** INP**Presenter:** John F. Schmedtje, Jr., President & CEO**Cognigenics, Inc.** (In-Person)**Categorical Listings:** CNS-Neurological, Genomics, Platform Technology**Location:** Eagle, Idaho United States**Year Established:** 2021 **Website:** www.cognigenics.io**Corporate Partners:** None**Funds Raised:** \$1.6M in Angel and Seed funding.**Presenter:** Tracy Brandmeyer, PhD, MSc, CTO

## Additional Presenting Company Profiles

## Conference Update

**Crossject SA** (Euronext:ALCJ) (In-Person)**Categorical Listings:** Drug Delivery, Neurology**Location:** Dijon, France**Year Established:** 2001 **Website:** www.crossject.com**Corporate Partners:** BARDA**Funds Raised:** €180M**Presenter:** Patrick Alexandre, CEO**Dscilab Co., Ltd.** (In-Person)**Categorical Listings:** Cardiovascular, Drug Delivery, Orphan-Rare Disease**Location:** Shanghai, China**Year Established:** 2022 **Website:** www.dscilaboratory.com**Corporate Partners:** Fosun Pharma**Funds Raised:** \$6M in 2022, more than \$8M in 2023.**Presenter:** Dan (Danielle) Chen, PhD, VP**Espervita Therapeutics** (In-Person)**Categorical Listings:** Endocrine-Metabolic, Fibrosis, Oncology**Location:** Plymouth, Michigan United States**Year Established:** 2018 **Website:** www.espervita.com**Corporate Partners:** Seeking corporate partners.**Funds Raised:** \$6M to date.**Presenter:** Spencer Heaton, MD, MBA, CEO**GeneLancet Biosciences, Inc.** (In-Person)**Categorical Listings:** Gene-Cell Therapy, Infectious Disease, Platform Technology**Location:** Doylestown, Pennsylvania United States**Year Established:** 2019 **Website:** www.genelancetbio.com**Corporate Partners:** Blumberg Institute on LgRNA-CRISPR treatment of chronic hepatitis B.**Funds Raised:** SBIR (\$0.3M), R21(\$0.3M, R33 potentially >\$1M), \$0.3M (private fund).**Presenter:** Minghong Zhong, PhD, CEO**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** (HKEX:1541) (In-Person)**Categorical Listings:** Antibodies, Immuno-oncology, Oncology**Location:** Shanghai, China**Year Established:** 2015 **Website:**

cn.immuneonco.com/science/index.html#STARDTPlatform

**Corporate Partners:** INP**Funds Raised:** Approximately \$259M since establishment, with over HK\$10B in market cap.**Presenter:** Wenzhi Tian, MD, PhD, Chairman, CEO & CSO**iQure Pharma** (In-Person)**Categorical Listings:** CNS-Neurological, Neuropathy, Platform Technology**Location:** Princeton, New Jersey United States**Year Established:** 2019 **Website:** www.iqurepharma.com**Corporate Partners:** INP**Funds Raised:** 2023 A2 \$1.8M oversubscribed, 2022 A1 \$1.1M; 2021-2019 Founders \$400K.**Presenter:** Paul Zolnierczyk, MSc, CEO**Lactiga US, Inc.** (In-Person)**Categorical Listings:** Antibodies, Immunology, Orphan-Rare Disease**Location:** North Brunswick Township, New Jersey United States**Year Established:** 2021 **Website:** www.lactiga.com**Corporate Partners:** iNP**Funds Raised:** \$1.7M**Presenter:** Rikin Mehta, PharmD, Co-Founder & CEO**Lynk Pharmaceuticals Co., Ltd.** (In-Person)**Categorical Listings:** Autoimmune, CNS-Neurological, Dermatology**Location:** Hangzhou, China**Year Established:** 2018 **Website:** www.lynkpharma.com**Corporate Partners:** The company's lead compound LNK01001 is partnered in greater China with Simcere for two indications.**Funds Raised:** Completed C2 funding round in 2023. C round financing of ¥322M.**Presenter:** Michael L. Vazquez, PhD, Co-Founder & Head of Chemistry**MEKanic Therapeutics, Inc.** (In-Person)**Categorical Listings:** Drug Discovery, Oncology**Location:** Minneapolis, Minnesota United States**Year Established:** 2015 **Website:** www.mekanistic.com**Corporate Partners:** Just beginning to explore dual registration and distribution partnerships in Asia.**Funds Raised:** \$10M+ in NIH grants, \$3M in Series A.**Presenter:** Judith (Judy) Leopold, PhD, CSO**Modulus Therapeutics, Inc.** (In-Person)**Categorical Listings:** Autoimmune, Functional Genomics, Gene-Cell Therapy**Location:** Seattle, Washington United States**Year Established:** 2020 **Website:** www.modulustherapeutics.com**Corporate Partners:** Undisclosed pharma collaborators.**Funds Raised:** \$6M**Presenter:** Max Darnell, PhD, CEO**NGGT Inc.** (In-Person)**Categorical Listings:** Biomanufacturing, Gene-Cell Therapy, Orphan-Rare Disease**Location:** Sacramento, California United States**Year Established:** 2020 **Website:** www.nggtbio.com**Corporate Partners:** INP**Funds Raised:** \$84M**Presenter:** Lixin Jiang, PhD, Co-Founder & CEO

## Conference Update

**Pattern Computer** (In-Person)

**Categorical Listings:** Artificial Intelligence (AI), Diagnostics, Drug Discovery

**Location:** Friday Harbor, Washington United States

**Year Established:** 2015 **Website:** www.patterncomputer.com

**Corporate Partners:** Partners include: Fred Hutchinson Cancer Center; Lawrence Berkeley and Los Alamos National Laboratories; Limerick Digital Cancer Research Centre; Karolinska Institutet; University of Washington; UC San Diego; AI.Hamburg.

**Funds Raised:** Over \$33M to date, in six rounds; current B Round is for \$40M, with \$11M in.

**Presenter:** Mark Anderson, PhD, MS, Chair & CEO

**RND Pharmaceuticals Inc.** (In-Person)

**Categorical Listings:** Autoimmune, Gastrointestinal, Gene-Cell Therapy

**Location:** New York, New York United States

**Year Established:** 2023 **Website:** www.rndpharmaceuticals.com

**Corporate Partners:** RND-101: Cell4Cure (Sweden), and RND-103: not disclosed yet.

**Funds Raised:** RND-101 and RND-103 were developed by the originator, up to the clinical stage at an investment of ~\$30M each.

**Presenter:** Ramon Mohanlal, MD, PhD, CEO

**Sagmos Therapeutics** (In-Person)

**Categorical Listings:** Cardiovascular, Mitochondrial Therapeutic, Renal

**Location:** Greenwich, Connecticut United States

**Year Established:** 2016 **Website:** INP

**Corporate Partners:** Discussions ongoing.

**Funds Raised:** Approximately \$10M.

**Presenter:** Anna Kazanchyan, MD, CEO

**Saphiros Ai Bio** (In-Person)

**Categorical Listings:** Gene-Cell Therapy, Regenerative Medicine

**Location:** Boston, Massachusetts United States

**Year Established:** 2021 **Website:** www.saphiros.ai

**Corporate Partners:** PPD is the company's clinical services partner, Patheon is its CDMO and it is partnered with Regenity to develop innovative bio absorbable scaffolds for select therapeutic applications.

**Funds Raised:** The company is a spin out from a KKR funded organization.

**Presenter:** Robin Y. Smith, CEO

**SHIFTBIO INC.** (In-Person)

**Categorical Listings:** Drug Discovery, Fibrosis, Gene-Cell Therapy

**Location:** Seoul, South Korea

**Year Established:** 2020 **Website:** www.shiftbio.net

**Corporate Partners:** RoosterBio (CMC), Dassault Systèmes (Collaborative Research).

**Funds Raised:** Attracted private investment of \$6M (2023).

**Presenter:** Gi-Hoon Nam, MD, PhD, Co-Founder & CEO

**Sinaptica Therapeutics Inc.** (In-Person)

**Categorical Listings:** CNS-Neurological, Machine Learning, Neurology

**Location:** Cambridge, Massachusetts United States

**Year Established:** 2021 **Website:** www.sinapticatx.com

**Corporate Partners:** The company signed an LOI with a hardware partner for developing its systems but is open to strategic partnerships as well.

**Funds Raised:** All previous Ph2 funding was non-dilutive, funded by grants. Recently closed a \$1.5M Seed (SAFE) round oversubscribed.

**Presenter:** Ken Mariash, CEO

**Trilo Therapeutics** (In-Person)

**Categorical Listings:** Antibodies, Drug Discovery, Oncology

**Location:** San Francisco, California United States

**Year Established:** 2017 **Website:** www.trilotx.com

**Corporate Partners:** The company has been selected in pharma-sponsored competitions for startups as winner (AbbVie, 2019; Amgen, 2020) or finalist (BMS, 2023).

**Funds Raised:** More than \$2.3M to date from Angel investors and NSF grant.

**Presenter:** Kurt Gish, PhD, President & CEO

**UgeneX Therapeutics** (In-Person)

**Categorical Listings:** Gene-Cell Therapy, Ophthalmic

**Location:** Shanghai, China

**Year Established:** 2021 **Website:** INP

**Corporate Partners:** Fosun Pharma

**Funds Raised:** Approximately \$6M

**Presenter:** Sijie Sun, PhD, Executive President

**VacV Biotherapeutics Limited** (In-Person)

**Categorical Listings:** Immuno-oncology, Oncology, Platform Technology

**Location:** London, United Kingdom

**Year Established:** 2022 **Website:** www.vacvbx.com

**Corporate Partners:** No corporate partners yet.

**Funds Raised:** \$10M to date. \$3M in equity and \$7M in grants.

**Presenter:** Glyn Edwards, MBA, Executive Chair

**Variant Bio, Inc.** (In-Person)

**Categorical Listings:** Bioinformatics, Drug Discovery, Genomics

**Location:** Seattle, Washington United States

**Year Established:** 2018 **Website:** www.variantbio.com

**Corporate Partners:** INP

**Funds Raised:** \$130M since November 2018 - Seed round in 2018, \$25M Series A in 2020, \$105M Series B in 2021.

**Presenter:** Andrew Farnum, CEO

## Additional Presenting Company Profiles

## Conference Update

**Westlake Genetech**

(In-Person)

**Categorical Listings:** Artificial Intelligence (AI), Drug Delivery, Gene-Cell Therapy**Location:** Hangzhou, China**Year Established:** 2021 **Website:**[www.westlakegenetech.com/en/index.html](http://www.westlakegenetech.com/en/index.html)**Corporate Partners:** Westlake Genetech is looking to license AAV variants targeting muscles, CNS, heart, and immune cells. The company is also looking for the co-development of an early-stage pipeline.**Funds Raised:** \$15M since 2021.**Presenter:** Lijia Ma, PhD, Scientific Founder**Zenon Biotech**

(In-Person)

**Categorical Listings:** Fibrosis, Oncology, Platform Technology**Location:** Woburn, Massachusetts United States**Year Established:** 2020 **Website:** [www.zenonbiotech.com](http://www.zenonbiotech.com)**Corporate Partners:** Zenon is actively seeking institutional investors and strategic partners.**Funds Raised:** \$5M**Presenter:** David Lagares, PhD, MSc, Founder & CEO**DigiMed Presenting Companies****Ultra Sight**

(In-Person)

**Categorical Listings:** Artificial Intelligence (AI), Cardiovascular, Diagnostics**Location:** Ness Ziona, Israel**Year Established:** 2018 **Website:** [www.ultrasight.com](http://www.ultrasight.com)**Corporate Partners:** EchoNous, Selvas, Healcerion, HeartNexus and Clarius are UltraSight's device manufacturer partners.**Funds Raised:** \$22.2M funds to date.**Presenter:** Davidi Vortman, CEO**YunQuan Biological Technology (Beijing) Co., Ltd.**

(In-Person)

**Categorical Listings:** Artificial Intelligence (AI), Autoimmune, Drug Discovery**Location:** Beijing, China**Year Established:** 2020 **Website:** [www.longtengjingyun.com](http://www.longtengjingyun.com)**Corporate Partners:** Collaborated with Professor Haiyan Liu from the University of Science and Technology of China.**Funds Raised:** To raise \$1B in financing in 2024.**Presenter:** Minghui Dong, PhD, CEO



## Conference Update

## SEED Presenting Companies

**Dionysus Digital Health, Inc** (In-Person)

**Categorical Listings:** Epigenetics, Machine Learning, Women's Health

**Location:** San Diego, California United States

**Year Established:** 2020 **Website:** www.dionysushealth.com

**Corporate Partners:** Several on-going discussions with female health clinics.

**Funds Raised:** Approximately \$950K pre-Seed, and \$415K from NIH RADx (Rapid Acceleration of Diagnostics).

**Presenter:** Andrea Cubitt, PhD, CEO

**Elenae Therapeutics, Inc.** (In-Person)

**Categorical Listings:** Cardiovascular, Fibrosis, Ophthalmic

**Location:** Berkeley, California United States

**Year Established:** 2021 **Website:** www.elenaetherapeutics.com

**Corporate Partners:** INP

**Funds Raised:** \$1.25M pre-Seed Angel investment.

**Presenter:** Anders Naar, PhD, CEO

**Embold Therapeutics, Inc.** (In-Person)

**Categorical Listings:** CNS-Neurological, Drug Discovery, Platform Technology

**Location:** Redwood City, California United States

**Year Established:** 2023 **Website:** www.emboldtx.com

**Corporate Partners:** The company does not have corporate partners currently.

**Funds Raised:** Minimal - Internally funded.

**Presenter:** Gjalt Huisman, PhD, CEO

**Eugit Therapeutics Inc** (In-Person)

**Categorical Listings:** Gene-Cell Therapy, Inflammation, Platform Technology

**Location:** San Carlos, California United States

**Year Established:** 2022 **Website:** www.eugitx.com

**Corporate Partners:** None

**Funds Raised:** \$500K in June 2022, \$200K in October 2022.

**Presenter:** Nizar Batada, PhD, CEO

**Narwhal Bio Inc.** (In-Person)

**Categorical Listings:** Gene-Cell Therapy, Immuno-oncology, Regenerative Medicine

**Location:** San Diego, California United States

**Year Established:** 2021 **Website:** www.narwhal.bio

**Corporate Partners:** INP

**Funds Raised:** INP

**Presenter:** Behrad Azimi, PhD, Co-Founder & CEO

**Niconox LLC** (Virtual)

**Categorical Listings:** CNS-Neurological, Drug Delivery

**Location:** Monmouth Junction, New Jersey United States

**Year Established:** 2022 **Website:** www.niconox.com

**Corporate Partners:** The company has been getting support from the provider of the inhaler technology that we modified using its own IP.

**Funds Raised:** None except the Founders' cash and effort.

**Presenter:** Igor Gonda, PhD, Executive Chairman & Co-Founder

**Novel Biotechnology Inc.** (In-Person)

**Categorical Listings:** Biomanufacturing, Gene-Cell Therapy, Platform Technology

**Location:** Woodbridge, Canada

**Year Established:** 2021 **Website:** www.novelbiologics.com

**Corporate Partners:** Working with 8 potential partners to deploy the technology.

**Funds Raised:** \$1.7M so far and planning to raise another \$1.5M to \$2M in next 6-12 months.

**Presenter:** Pankaj Khanna, MSc, President

**Papillon Biosciences, Inc.** (Virtual)

**Categorical Listings:** Drug Delivery, Endocrine-Metabolic, Platform Technology

**Location:** Pasadena, California United States

**Year Established:** 2022 **Website:** www.papillonbio.com

**Corporate Partners:** PapillonBio is interested in exploring partnerships with pharmaceutical companies interested in the development of novel treatments for diabetes.

**Funds Raised:** Seeking to raise Seed round funding. To date funded by management team.

**Presenter:** Matthew J. Pfeffer, EVP & CFO

**TMAB Therapeutics, Inc.** (In-Person)

**Categorical Listings:** Antibodies, Oncology, Orphan-Rare Disease

**Location:** Houston, Texas United States

**Year Established:** 2023 **Website:** www.nandilifesciences.com

**Corporate Partners:** Texas Medical Center (TMC) and TMC Accelerator for Cancer Therapeutics.

**Funds Raised:** INP

**Presenter:** Tinashe Chandauka, CEO